

Questionnaire

General Data:

Gender (Male/Female/Other)

Age

Do you work in the medical field? (No, contact with the medical field, doctor, nurse)

What Autoimmune/immune mediated disease do you have? (Multiple-choice question)

What is your background therapy? (Multiple-choice question)

Do you take Biologic DMARDs? (Yes/No)

When was your immune disorder diagnosed? (Open-ended question)

When was the last date of the disease aggravation (flare)? (Open-ended question)

Do you have pulmonary damage as a consequence of your immune disease? (Yes/No)

What other pathologies do you have? (Multiple-choice question)

A. Access to medical care during the pandemic

Have you encountered difficulties in accessing medical care since the beginning of the pandemic? (Yes/No)

If yes, why? (postponed visits for fear of infection/ my regular hospital became a COVID-19 support facility/ the appointments were difficult to obtain/ other response)

If no, how? (did not require medical care/ assessed by the attending physician at their private practice and using telemedicine/ addressed to primary care physicians/ the hospital continued its regular activity)

B. SARS-CoV-2 infection in subjects with autoimmune and immune-mediated diseases

Did you have symptoms resembling COVID-19? (Yes/No)

Did you get tested for COVID-19? (Yes, the result was positive-was in contact with a positive person/Yes, the result was positive-without contact with a positive person/Yes, the result was negative/No, because I had no contact with positive people and nor symptoms/No, because I had no symptoms, although I had contact with positive people/No, although I had symptoms, because I was afraid of hospitalization)

Have you tested positive for COVID19? (Yes/No)

If yes, by which type of test? (RT-PCR/rapid test)

Mention the date of COVID-19 diagnosis. (Open-ended question)

What symptoms did you have? (Multiple-choice question)

How was COVID-19 managed? (hospitalised, but I don't think I needed to/ hospitalised, because that was the law/ hospitalised (I needed to)/monitored at home/not monitored)

Did you have pulmonary involvement secondary to SARS-CoV-2 infection? (No/ Not investigated/ Yes- mention the degree of the involvement)

If admitted to the hospital, did you require oxygenotherapy? (Yes/No)

Did you require ICU admission? (Yes/No)

Mention the length of hospitalisation. (Open-ended question)

What treatment was recommended for COVID-19? (Multiple-choice question)

How was the treatment for your immune disease managed during the infection? (continued without changes/ doses have been adjusted/ immunosuppressive therapy has been stopped)

What was the evolution of the immune pathology during the pandemic? (Stationary/ it got worse- have not had COVID/ got worse after COVID)

C. Perspective, basic knowledge and willingness to be immunized against SARS-CoV-2

Do you consider yourself informed regarding the national SARS-CoV-2 immunization program? (Yes/No)

Where did you get the information about the vaccination program? (Multiple-choice question)

Do you want to get vaccinated against SARS-CoV-2? (Yes/No, because I don't think I'll get in touch with infected people/ No, because I had COVID-19/No, because I'm afraid of possible side effects/ No, because I don't think it works/ No, because the doctor advised me not to get vaccinated)

Do you know the possible side effects of the SARS-CoV-2 vaccine? (Semi-structured, multiple-choice question)

Do you consider yourself at higher risk of developing side effects given your immune pathology? (No, I have no higher risk than the rest of the population/ Yes, but I will take the risk/ Yes and I don't want to take the risk/ I don't know if I'm at risk or not)

Have you talked to your doctor about SARS-CoV-2 vaccination? (Semi-structured, multiple-choice question)

What is your attitude towards the FLU vaccine? (vaccinated annually/ never vaccinated/ usually got vaccinated but not every year/frequently/ vaccinated this year)

Did you get the Coronavirus Vaccine? (Yes/No)

Table S1. The incidence of COVID-19 among the autoimmune and immune mediated diseases reported *.

| Immune disease | Covid-19 patients positive (n = 135) | Covid-19 negative (n = 516) | p value |
|--|--------------------------------------|-----------------------------|--------------|
| Rheumatic Diseases and Musculoskeletal Conditions | | | |
| Rheumatoid arthritis | 16 (11.9%) | 88 (17.1%) | 0.149 |
| Systemic lupus erythematosus | 22 (16.3%) | 77 (14.9%) | 0.687 |
| Sjögren's syndrome/SICCA | 16 (11.9%) | 64 (12.4%) | 1 |
| Ankylosing spondylitis | 13 (9.6%) | 56 (10.9%) | 0.755 |
| Psoriatic arthritis/psoriasis | 14 (10.4%) | 41 (7.9%) | 0.385 |
| Systemic sclerosis/limited scleroderma | 8 (5.9%) | 23 (4.5%) | 0.496 |
| Antiphospholipid syndrome | 6 (4.4%) | 20 (3.9%) | 0.805 |
| Dermatomyositis/polymyositis | 1 (0.7%) | 11 (2.1%) | 0.476 |
| Mixed connective tissue disease | 2 (1.5%) | 8 (1.6%) | 1 |
| Behçet's disease | 0 (0%) | 3 (0.6%) | 1 |
| Granulomatosis with polyangiitis | 4 (3%) | 1 (0.2%) | 0.007 |
| Microscopic polyangiitis | 1 (0.7%) | 2 (0.4%) | 0.503 |
| Giant cell arteritis | 2 (1.5%) | 3 (0.6%) | 0.278 |
| Takayasu arteritis | 1 (0.7%) | 0 (0%) | 0.207 |
| Polyarteritis nodosa | 0 (0%) | 1 (0.2%) | 1 |
| Henoch-Schönlein purpura | 0 (0%) | 1 (0.2%) | 1 |
| Cryoglobulinemia | 0 (0%) | 1 (0.2%) | 1 |
| Gastroenterological and hepatic diseases | | | |
| Inflammatory bowel disease | 14 (10.4%) | 30 (5.8%) | 0.081 |
| Celiac disease | 4 (3%) | 16 (3.1%) | 1 |
| Primary biliary cholangitis | 3 (2.2%) | 6 (1.2%) | 0.402 |
| Autoimmune hepatitis | 2 (1.5%) | 10 (1.9%) | 1 |
| Neurological diseases | | | |
| Myasthenia gravis | 7 (5.2%) | 23 (4.5%) | 0.651 |
| Multiple sclerosis | 1 (0.7%) | 24 (4.7%) | 0.041 |
| Autoimmune encephalomyelitis | 1 (0.7%) | 1 (0.2%) | 0.372 |
| Hematological diseases | | | |
| Hemolytic anemia | 1 (0.7%) | 1 (0.2%) | 0.372 |
| Paroxysmal Nocturnal Hemoglobinuria | 1 (0.7%) | 0 (0%) | 0.207 |
| Autoimmune thrombocytopenia | 0 (0%) | 3 (0.6%) | 1 |
| Cutaneous diseases | | | |
| Vitiligo | 2 (1.5%) | 8 (1.6%) | 1 |
| Cutaneous lupus | 1 (0.7%) | 1 (0.2%) | 0.372 |
| Cutaneous vasculitis | 1 (0.7%) | 3 (0.6%) | 1 |
| Pemphigus | 0 (0%) | 1 (0.2%) | 1 |
| Other immune mediated diseases | | | |
| Autoimmune thyroid disease | 24 (17.8%) | 116 (22.5%) | 0.289 |
| Sarcoidosis | 4 (3%) | 4 (0.8%) | 0.062 |
| Type 1 diabetes mellitus | 1 (0.7%) | 2 (0.4%) | 0.503 |
| Hyper IgD syndrome | 0 (0%) | 1 (0.2%) | 1 |

* Participants may report more than one autoimmune/immune mediated disease.